Chikungunya Virus Clinical Trial
Official title:
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], aluminum hydroxide adjuvanted).
Primary Objectives: 1. To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 (40 µg CHIKV VLP, alum-adjuvanted) as measured 21 days (Day 22) after vaccination. 2. To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 as measured 7 days (Day 8), 14 days (Day 15), and 56 days (Day 57) after vaccination. Secondary Objectives: 1. To assess safety of a single adjuvanted dose of PXVX0317 in healthy adults. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05072080 -
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
|
Phase 3 | |
| Terminated |
NCT00391313 -
CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease
|
Phase 3 | |
| Completed |
NCT05349617 -
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
|
Phase 3 | |
| Completed |
NCT02305732 -
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
|
||
| Completed |
NCT01489358 -
Chikungunya Virus Vaccine Trial in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03325075 -
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects
|
Phase 1 |